Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics director Baiteng Zhao received a grant of stock options as compensation. On the grant date, Zhao was awarded options for 38,040 shares of common stock at an exercise price of $4.16 per share, expiring on June 12, 2036. All options vest 100% after about one year or just before the next annual stockholder meeting, as long as Zhao continues serving the company.
Whitehawk Therapeutics director Emma Reeve received a stock option grant, giving her the right to buy 38,040 shares of common stock at an exercise price of $4.16 per share. The option was granted as a compensation award with no cash paid at grant.
The option expires on June 12, 2036. All 38,040 shares subject to the option vest 100% on the earlier of one year after the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting, as long as she continues as a service provider. Following this grant, she holds options covering 38,040 shares directly.
Whitehawk Therapeutics director Richard E. Maroun received a grant of stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036. All 38,040 option shares will vest in a single tranche, subject to his continued service, on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting following that date. After this award, he holds 38,040 derivative securities directly.
Whitehawk Therapeutics director Mohammad Hirmand received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036.
All 38,040 option shares will vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the next annual stockholder meeting, as long as he continues as a service provider. Following this grant, he holds 38,040 stock options directly from this award.
Whitehawk Therapeutics director Neil Desai received a new stock option grant. The Form 4 shows an award of options covering 38,040 shares of common stock at an exercise price of $4.1600 per share, expiring on June 12, 2036.
All 38,040 option shares vest in a single tranche, subject to Mr. Desai continuing as a service provider. Vesting occurs on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting after that grant date.
Whitehawk Therapeutics director Caley Castelein received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036. Following this grant, Castelein holds stock options for 38,040 underlying shares directly.
According to the award terms, all 38,040 option shares vest 100% if Castelein continues as a service provider until the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately prior to the next annual stockholder meeting after that grant date.
Whitehawk Therapeutics, Inc. reported that director and 10% owner Behzad Aghazadeh was granted stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036.
According to the terms, all 38,040 underlying shares vest in a single tranche if the reporting person continues to be a service provider through the earlier of the one-year anniversary of the grant date or the day immediately before the next annual shareholder meeting, with a grant date of June 12, 2026. The filing is made jointly by Avoro Capital Advisors LLC, Avoro Ventures LLC, and Dr. Aghazadeh, who each disclaim beneficial ownership beyond their pecuniary interest.
Whitehawk Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where investors voted on director elections, executive pay and the company’s auditor. A total of 40,375,023 common shares, representing approximately 82% of voting power as of April 17, 2026, were present, establishing a quorum.
Stockholders elected three Class III directors – Behzad Aghazadeh, Ph.D., Richard Maroun and Emma Reeve – to terms ending at the 2029 annual meeting. On an advisory basis, stockholders approved the compensation of named executive officers. They also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Whitehawk Therapeutics is registering the resale of up to 22,321,887 shares of its common stock. These Shares consist of 4,330,866 outstanding shares and 17,991,021 shares issuable upon exercise of pre-funded warrants sold in a Private Placement closed May 14, 2026. The Company will receive no proceeds from resales under this prospectus and has agreed to bear registration expenses per a Registration Rights Agreement executed with the purchasers. The Private Placement raised approximately $87.5 million at a purchase price of $3.92 per share (and $3.9199 per pre-funded-warrant share), and certain holders are subject to Beneficial Ownership Limitations (4.99%, 9.99% or 19.99%, at holder election).